199113-95-6Relevant articles and documents
Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives
Madhavan, Gurram R,Chakrabarti, Ranjan,Vikramadithyan, Reeba K,Mamidi, Rao N.V.S,Balraju,Rajesh,Misra, Parimal,Kumar, Sunil K.B,Lohray, Braj B,Lohray, Vidya B,Rajagopalan, Ramanujam
, p. 2671 - 2680 (2007/10/03)
A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARγ transactivation assay was performed in HEK 293T cells. PMT13 showed the best biological activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy] phenylmethyl]thiazolidine-2,4-dione) showed better plasma glucose, triglyceride and insulin-lowering activity in db/db mice than rosiglitazone and pioglitazone. PMT13 showed better PPARγ transactivation than the standard compounds. Pharmacokinetic study in Wistar rats showed good systemic exposure of PMT13. Twenty-eight day oral toxicity study in Wistar rats did not show any treatment-related adverse effects.
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
-
, (2008/06/13)
The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically accep